The growth track for Oramed Pharmaceuticals Inc. (ORMP) has changed recently

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) stock fell -0.97% on Monday to $2.04 against a previous-day closing price of $2.06. With 1.93 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.28 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.0700 whereas the lowest price it dropped to was $1.9850. The 52-week range on ORMP shows that it touched its highest point at $13.73 and its lowest point at $1.81 during that stretch. It currently has a 1-year price target of $19.60. Beta for the stock currently stands at 2.08.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ORMP was down-trending over the past week, with a drop of -9.33%, but this was down by -75.36% over a month. Three-month performance dropped to -69.91% while six-month performance fell -76.66%. The stock lost -79.44% in the past year, while it has lost -83.04% so far this year. A look at the trailing 12-month EPS for ORMP yields -1.04 with Next year EPS estimates of -0.81.

Float and Shares Shorts:

At present, 39.10 million ORMP shares are outstanding with a float of 37.06 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.0 million, which was 7.72% higher than short shares on Sep 14, 2022. In addition to Mr. Nadav Kidron Esq. as the firm’s Pres, CEO & Exec. Chairman, Mr. David Silberman CPA serves as its CFO & Treasurer.

Institutional Ownership:

Through their ownership of 17.31% of ORMP’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.73% of ORMP, in contrast to 12.44% held by mutual funds. Shares owned by individuals account for 1.88%. As the largest shareholder in ORMP with 1.29% of the stake, Millennium Management LLC holds 503,031 shares worth 503,031. A second-largest stockholder of ORMP, Morgan Stanley & Co. LLC, holds 475,998 shares, controlling over 1.22% of the firm’s shares. Jess S. Morgan & Co., Inc. is the third largest shareholder in ORMP, holding 366,401 shares or 0.94% stake. With a 0.26% stake in ORMP, the KSM ETF is the largest stakeholder. A total of 99,914 shares are owned by the mutual fund manager. The iShares Tr. – Micro Cap ETF, which owns about 0.20% of ORMP stock, is the second-largest Mutual Fund holder. It holds 79,370 shares valued at 0.95 million. BlueStar TA-BIGITech Israel Techn holds 0.20% of the stake in ORMP, owning 76,600 shares worth 0.92 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ORMP since 4 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ORMP analysts setting a high price target of $35.00 and a low target of $3.00, the average target price over the next 12 months is $18.75. Based on these targets, ORMP could surge 1615.69% to reach the target high and rise by 47.06% to reach the target low. Reaching the average price target will result in a growth of 819.12% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ORMP will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of -$0.64 being high and -$1.05 being low. For ORMP, this leads to a yearly average estimate of -$0.91. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Oramed Pharmaceuticals Inc. surprised analysts by $0.07 when it reported -$0.18 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was -$0.03. Based on analyst estimates, the high estimate for the next quarter is $0.03 and the low estimate is -$0.32. The average estimate for the next quarter is thus -$0.19.

Summary of Insider Activity:

Insiders traded ORMP stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 25,000 shares were sold. The number of buy transactions has increased to 14 while that of sell transactions has risen to 6 over the past year. The total number of shares bought during that period was 486,167 while 64,945 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *